Are Opioids Needed After ACL Reconstruction

Sponsor
Emory University (Other)
Overall Status
Recruiting
CT.gov ID
NCT04285853
Collaborator
Orthopedic Research and Education Foundation (Other)
100
3
2
25.5
33.3
1.3

Study Details

Study Description

Brief Summary

As the public health sector continues to confront the opioid epidemic, orthopaedic surgeons must revisit pain management protocols to reduce unnecessary opioid prescriptions. The long-term goal is to reduce opioid use and residual opioids in circulation.

Condition or Disease Intervention/Treatment Phase
Phase 4

Detailed Description

As the public health sector continues to confront the opioid epidemic, orthopaedic surgeons must revisit pain management protocols to reduce unnecessary opioid prescriptions. The long-term goal is to reduce opioid use and residual opioids in circulation. The purposes are to 1) conduct a double-blinded randomized controlled trial to determine the effectiveness of opioid versus non-opioid medications on post-surgical pain, and 2) examine predictors of opioid usage in individuals following Anterior Cruciate ligament (ACL) reconstruction. Patients will use an innovative Smartphone application to track pain and medication usage. Additionally, patients will complete quality of life and pain catastrophizing questionnaires, as well as undergo pain threshold testing, to be used in a model to determine predictors of greater post-surgical opioid use. This study will provide information on non-opioid alternatives and specific predictors of post-surgical opioid use that can be used to develop prescribing protocols. These findings will help orthopaedic surgeons make informed decisions when tailoring individualized prescriptions for patients following ACL reconstruction. Importantly, findings will be readily translatable into research to reduce opioid use in other orthopaedic surgical cohorts as well. Our ultimate goal is to lessen the burden of the opioid epidemic on not only our orthopaedic patients, but also society, by minimizing the number of opioids left in circulation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Prospective, double-blind, randomized controlled clinical trialProspective, double-blind, randomized controlled clinical trial
Masking:
Double (Participant, Investigator)
Masking Description:
Both participants and PI (orthopaedic surgeon) will be blinded. Placebo pills will be closely matched to oxycodone pills, so patients will not know to which group they are allocated. The PI will be blinded to group allocation.
Primary Purpose:
Treatment
Official Title:
Are Opioids Needed: A Double-Blinded, Randomized Controlled Trial and Examination of Predictors of Opioid Use Following ACL Reconstruction
Actual Study Start Date :
Sep 16, 2020
Anticipated Primary Completion Date :
Nov 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Oxycodone Arm

Patients in this opioid group will receive 15 oral opioid tablets (5 mg oxycodone) Patients will also receive 8 "rescue" medications, in the Oxycodone arm will be placebo "rescue" medications. All participants will also receive the following as part of standard of care: Oral non-opioid (1000 mg acetaminophen), every 8 hours. Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery. Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block. Intraoperative education on post-surgical pain management.

Drug: Oxycodone
5 mg oxycodone pills every 4-6 hrs if pain level 7 or higher on Numeric rating scale 1-10
Other Names:
  • Xtampza ER, Oxaydo, Roxicodone, and Oxycontin
  • Placebo Comparator: Placebo Arm

    Patients in placebo group will receive 15 placebo tablets. All patients will also receive 8 "rescue" medications: Patients who randomize to the non-opioid arm will receive 5mg oxycodone "rescue" tablets. All participants will also receive the following as part of standard of care: Oral non-opioid (1000 mg acetaminophen), every 8 hours. Prescription of non-opioid non-steroidal anti-inflammatory medication (naproxen 500 mg) to be used 2x/day post-surgery. Standardized multimodal intra- and post-operative protocols, including an adductor canal peripheral nerve block. Intraoperative education on post-surgical pain management.

    Drug: Placebo oral tablet
    Placebo tablets (both trial and "rescue") will be matched to size, shape, color, and texture of oxycodone tablets.

    Outcome Measures

    Primary Outcome Measures

    1. Change in pain level: Numeric Rating Scale [Postoperative days 0-6]

      Patients will record pain levels on Numeric Rating Scale 1-10, where 1 is minimal pain and 10 is associated with highest level of pain (worse outcome).

    Secondary Outcome Measures

    1. Change in Quality of life: Euro Quality of Life Index (Euro QoL 5-D 5-L) EQ-5D [Postoperative days 0-6, 6 weeks post-surgery]

      Quality of life will be measured with the instrument Euro Quality of Life Index (Euro QoL 5-D 5-L) EQ-5D is a standardized measure of health status that measures five dimensions, Mobility, Self-care, Daily activities, Pain/Discomfort, Anxiety/ Depression. Each dimension can be rated at five levels: from no problems to major problems. The five dimensions can be summed into a descriptive health state with 11111 representing no problems in any of the five health dimensions and 55555 indicating major problems in any of the five health dimensions.

    2. Change in Pain catastrophizing scale (PCS) [Postoperative days 0-6, 6 weeks post-surgery]

      It will be determined with the Pain Catastrophizing Scale (PCS). Pain catastrophizing is described as "an exaggerated negative mental set brought to bear during actual or anticipated painful experience." In other words, it is a feeling of helplessness. The PCS is a 13-item questionnaire that inquires about thoughts and feelings a patient experiences when in pain. Responses are recorded on a 5-point Likert scale ("not at all" to "all the time"). A total score is yielded ranging from 0-52. Higher score is associated with worse outcome.

    3. Change in Pain threshold testing [Postoperative days 0-6, 6 weeks post-surgery]

      will be conducted with digital pressure dolorimeter (Wagner Force One Model FDIX 50TM, Wagner Instruments). Pressure dolorimeters are devices that measure pressure/pain threshold. The device will be held perpendicular to the areas to be tested. The force will be increased at a constant rate of 1 kg/cm2. Patients will be instructed to express pain either by saying "ouch" or raising their hand when pain is felt. The force read on the digital dolorimeters will be recorded. This procedure will be repeated 3 times. Both right and left sides will be tested.

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    14 Years to 40 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Males and females

    • Aged 14-40 years

    • Scheduled for primary (Anterior cruciate ligament) ACL reconstruction using quadriceps tendon autograft.

    Exclusion Criteria:
    • Revision and/or contralateral ACL reconstruction procedures

    • Allergies to local anesthetics

    • Chronic pain medication use

    • Weight <50 kg, local infections

    • Known coagulopathies,

    • Liver dysfunction or renal failure

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 The Emory Clinic Atlanta Georgia United States 30324
    2 Emory clinic at Executive Park Atlanta Georgia United States 30329
    3 Emory Orthopedic and spine Hospital Tucker Georgia United States 30084

    Sponsors and Collaborators

    • Emory University
    • Orthopedic Research and Education Foundation

    Investigators

    • Principal Investigator: John Xerogeanes, MD, Emory University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    John Xerogeanes, Professor, Emory University
    ClinicalTrials.gov Identifier:
    NCT04285853
    Other Study ID Numbers:
    • IRB00116728
    First Posted:
    Feb 26, 2020
    Last Update Posted:
    May 10, 2022
    Last Verified:
    May 1, 2022
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Product Manufactured in and Exported from the U.S.:
    No
    Keywords provided by John Xerogeanes, Professor, Emory University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of May 10, 2022